FYR Bio, a biotechnology company leveraging extracellular vesicles (EVs) to create an end-to-end solution for new precision medicine tools, today announced it has closed a new $8 million round of funding. The Sontag Innovation Fund (a venture subsidiary of The Sontag Foundation) and the Yuvaan Tiwari Foundation join long-standing investor Two Bear Capital. Proceeds will accelerate FYR’s continued expansion in oncology and added emphasis in neuroscience, including neuro-oncology and neurodegeneration.
“This financing enables us to scale what our partners value most: high-quality, blood-based insights that guide decisions in hard-to-access diseases,” said Chris Booth, PhD, Chief Executive Officer of FYR. “We are expanding our neuro-oncology and neurodegeneration programs while actively growing our general oncology portfolio with existing and new partners.”
Read More – PredictAP Raises Additional $5M in Funding
“The Sontag Innovation Fund invests in technologies with the potential to materially improve outcomes for people with brain cancer,” said Scott Davis, PhD, Managing Director, The Sontag Innovation Fund. “FYR’s ability to enrich tumor and brain-derived EV signals from a simple blood draw and translate those signals into clinically actionable biomarkers is strongly aligned with our mission. We’re especially excited to support their continued growth in neuroscience and neuro-oncology.”
“FYR has combined chemistry innovations with advanced AI analytics to turn complex biology into reliable, usable data,” said Avery Sonnenberg, PhD, Principal at Two Bear Capital. “Their platform is scaling across solid tumors and also unlocks CNS applications where clean, noninvasive signals are notoriously hard to capture. We’re excited to support the natural expansion of their platform into neuro-oncology and neurodegeneration alongside continued growth in oncology.”
“For children with aggressive brain tumors, progress has been far too slow. Our foundation is committed to backing bold science that can change that reality,” said Parvati Tiwari, President and Co-Founder of the Yuvaan Tiwari Foundation. “FYR’s EVO platform provides a non-invasive way to gain early insights and better guide treatment decisions—ultimately leading to improved outcomes for patients. We are proud to support this work and help advance its potential in neuro-oncology.”
Recent progress in brain cancer and neurodegeneration
Over the past year, FYR has expanded their CNS-focused collaborations and matured their clinical datasets. In brain cancer, FYR reported data showing that their blood‑based, AI‑enabled technology can distinguish adult malignant gliomas from healthy controls, with 100% specificity and 89% sensitivity (AUC of 0.99), using a panel of proteins measured from brain-derived EVs. These findings were presented at the 29th Annual Meeting of the Society for Neuro‑Oncology (SNO) and have the potential to support various high‑value unmet needs in neuro‑oncology, such as disease monitoring. In neurodegeneration, FYR is advancing Parkinson’s disease biomarker programs aimed at patient stratification and objective pharmacodynamic readouts in longitudinal samples; FYR’s Parkinson’s work was recently featured in Inside Precision Medicine.
Read More – Moneta Health Raises $4.5M in Funding
